RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.
暂无分享,去创建一个
P. Lønning | S. Knappskog | C. Busch | J. Lillehaug | J. Varhaug | L. M. Myklebust | T. Aloysius | F. Pendino | C. Busch | J. Lillehaug | C. Busch | Line M. Myklebust
[1] C. Purdie,et al. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer , 2010, International journal of cancer.
[2] P. Lønning,et al. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. , 2010, European journal of cancer.
[3] P. Lønning. Molecular basis for therapy resistance , 2010, Molecular oncology.
[4] Daniel Bottomly,et al. Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq , 2010, Nucleic acids research.
[5] M. Rivera,et al. A Novel Wilms Tumor 1 (WT1) Target Gene Negatively Regulates the WNT Signaling Pathway* , 2010, The Journal of Biological Chemistry.
[6] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[7] N. Zeleznik-Le,et al. Structure of the MLL CXXC domain–DNA complex and its functional role in MLL-AF9 leukemia , 2010, Nature Structural &Molecular Biology.
[8] Min Zhang,et al. The CXXC finger 5 protein is required for DNA damage-induced p53 activation , 2009, Science in China Series C: Life Sciences.
[9] I. Jonassen,et al. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. , 2009, Blood.
[10] M. García-Cuéllar,et al. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2 , 2009, Oncogene.
[11] O. Hermanson,et al. CXXC5 Is a Novel BMP4-regulated Modulator of Wnt Signaling in Neural Stem Cells* , 2009, Journal of Biological Chemistry.
[12] A. Eychène,et al. A new MAFia in cancer , 2008, Nature Reviews Cancer.
[13] S. Pradhan,et al. CXXC domain of human DNMT1 is essential for enzymatic activity. , 2008, Biochemistry.
[14] Gianluca Bontempi,et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.
[15] T. Yeatman,et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. , 2008, Cancer research.
[16] M. Bycroft,et al. Solution structure of the nonmethyl‐CpG‐binding CXXC domain of the leukaemia‐associated MLL histone methyltransferase , 2006, The EMBO journal.
[17] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] S. Wageningen,et al. ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells , 2005, Leukemia.
[20] M. Cleary,et al. Binding to Nonmethylated CpG DNA Is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein , 2004, Molecular and Cellular Biology.
[21] M. Katoh,et al. Identification and characterization of human CXXC10 gene in silico. , 2004, International journal of oncology.
[22] A. Bird,et al. Mbd1 Is Recruited to both Methylated and Nonmethylated CpGs via Distinct DNA Binding Domains , 2004, Molecular and Cellular Biology.
[23] K. Munger,et al. Id Proteins - Tumor Markers or Oncogenes? , 2002, Cancer biology & therapy.
[24] T. Aas,et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.
[25] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[26] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[27] Jiri Bartek,et al. Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.
[28] D. George,et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.
[29] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[30] F. Alt,et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas , 1983, Cell.